These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 1694418)
1. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases. Goto S; Hirano A; Matsumoto S Ann Neurol; 1990 May; 27(5):520-7. PubMed ID: 1694418 [TBL] [Abstract][Full Text] [Related]
2. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230 [TBL] [Abstract][Full Text] [Related]
3. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Goto S; Hirano A; Matsumoto S Ann Neurol; 1989 Dec; 26(6):766-70. PubMed ID: 2557795 [TBL] [Abstract][Full Text] [Related]
4. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211 [TBL] [Abstract][Full Text] [Related]
5. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422 [TBL] [Abstract][Full Text] [Related]
6. Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ito H; Goto S; Sakamoto S; Hirano A Ann Neurol; 1992 Oct; 32(4):543-50. PubMed ID: 1456738 [TBL] [Abstract][Full Text] [Related]
7. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
8. Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Sebeo J; Hof PR; Perl DP Acta Neuropathol; 2004 Jun; 107(6):497-503. PubMed ID: 15024581 [TBL] [Abstract][Full Text] [Related]
9. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Chaturvedi RK; Shukla S; Seth K; Agrawal AK Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803 [TBL] [Abstract][Full Text] [Related]
11. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Betarbet R; Greenamyre JT Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489 [TBL] [Abstract][Full Text] [Related]
12. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. de la Monte SM; Wells SE; Hedley-Whyte T; Growdon JH Ann Neurol; 1989 Sep; 26(3):309-20. PubMed ID: 2802531 [TBL] [Abstract][Full Text] [Related]
13. [The neuropathology of Parkinson syndrome]. Gray F Rev Neurol (Paris); 1988; 144(4):229-48. PubMed ID: 2843979 [TBL] [Abstract][Full Text] [Related]
14. Chronic nicotine treatment differentially regulates substance P and tyrosine hydroxylase immunoreactivity in substantia nigra ipsilateral to a unilateral lesion. Janson AM; Fuxe K Exp Neurol; 1997 Aug; 146(2):575-86. PubMed ID: 9270071 [TBL] [Abstract][Full Text] [Related]
15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Jellinger KA Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452 [TBL] [Abstract][Full Text] [Related]
18. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Anichtchik OV; Rinne JO; Kalimo H; Panula P Exp Neurol; 2000 May; 163(1):20-30. PubMed ID: 10785440 [TBL] [Abstract][Full Text] [Related]
19. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism. Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469 [TBL] [Abstract][Full Text] [Related]
20. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. Sajadi A; Bauer M; Thöny B; Aebischer P J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]